PMID- 29227976 OWN - NLM STAT- MEDLINE DCOM- 20181211 LR - 20181211 IS - 1423-002X (Electronic) IS - 0378-7346 (Linking) VI - 83 IP - 5 DP - 2018 TI - Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation. PG - 443-454 LID - 10.1159/000480011 [doi] AB - OBJECTIVE: To investigate whether ulipristal acetate (UPA) treatment modifies the expression of progesterone receptor (PR), its nuclear cofactors steroid receptor coactivator-1 (SRC1) and nuclear corepressor-1 (NCoR1), prosurvival factor B-cell lymphoma 2 (Bcl-2), and Akt in uterine myomas. PATIENTS: Prospective study of 59 women with symptomatic myomas undergoing myomectomy. Forty-two patients were treated preoperatively with UPA; the remaining 17 were not and they served as controls. METHOD: Tissue microarrays were obtained from surgical specimens and immunohistochemistry was performed. Blinded quantification of expression of PR (PR-A vs. PR-B), coactivator SRC1 and corepressor NCoR1, and prosurvival factor Bcl-2, and Akt and evaluation of Akt phosphorylation levels. RESULTS: Compared with the control group, UPA does not alter PR protein levels or expression patterns in myomas, and the PR-A/PR-B ratio was similar, as well as cytoplasmic or nuclear expression of cofactors SRC1 and NCoR1. Bcl-2 was heterogeneously expressed throughout the samples and no significant modification in expression was evidenced. No significant difference was found in Akt expression and phosphorylation between treated and untreated myomas. CONCLUSION: This study did not find any significant change in the expression of the studied factors in myomas after UPA exposure. In conclusion, various theories on myomas cells proposed on the basis of in vitro studies are not supported in vivo. CI - (c) 2017 S. Karger AG, Basel. FAU - Courtoy, Guillaume E AU - Courtoy GE AD - Pole de Gynecologie, Institut de Recherche Experimentale et Clinique, Universite Catholique de Louvain, Brussels, Belgium. FAU - Donnez, Jacques AU - Donnez J AD - Societe de Recherche pour L'Infertilite (SRI), Brussels, Belgium. FAU - Marbaix, Etienne AU - Marbaix E AD - Department of Pathology, Cliniques Universitaires St-Luc, Woluwe-Saint-Lambert, Belgium. AD - Cell Biology Unit, de Duve Institute, Universite Catholique de Louvain, Louvain-la-Neuve, Belgium. FAU - Barreira, Matilde AU - Barreira M AD - Pole de Gynecologie, Institut de Recherche Experimentale et Clinique, Universite Catholique de Louvain, Brussels, Belgium. FAU - Luyckx, Mathieu AU - Luyckx M AD - Gynecology Department, Cliniques Universitaires St-Luc, Brussels, Belgium. FAU - Dolmans, Marie-Madeleine AU - Dolmans MM AD - Pole de Gynecologie, Institut de Recherche Experimentale et Clinique, Universite Catholique de Louvain, Brussels, Belgium. AD - Gynecology Department, Cliniques Universitaires St-Luc, Brussels, Belgium. LA - eng PT - Journal Article DEP - 20171211 PL - Switzerland TA - Gynecol Obstet Invest JT - Gynecologic and obstetric investigation JID - 7900587 RN - 0 (Co-Repressor Proteins) RN - 0 (Norpregnadienes) RN - 0 (Protein Isoforms) RN - 0 (Proto-Oncogene Proteins c-bcl-2) RN - 0 (Receptors, Progesterone) RN - 0 (progesterone receptor B) RN - EC 2.3.1.48 (NCOA1 protein, human) RN - EC 2.3.1.48 (Nuclear Receptor Coactivator 1) RN - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) RN - YF7V70N02B (ulipristal acetate) SB - IM MH - Adult MH - Case-Control Studies MH - Co-Repressor Proteins MH - Female MH - Humans MH - Leiomyoma/drug therapy/*metabolism/pathology MH - Norpregnadienes/therapeutic use MH - Nuclear Receptor Coactivator 1/*metabolism MH - Phosphorylation MH - Prospective Studies MH - Protein Isoforms MH - Proto-Oncogene Proteins c-akt/*metabolism MH - Proto-Oncogene Proteins c-bcl-2/*metabolism MH - Receptors, Progesterone/*metabolism/therapeutic use MH - Uterine Neoplasms/drug therapy/*metabolism/pathology OTO - NOTNLM OT - Progesterone receptor OT - Akt OT - Bcl-2 OT - Immunohistochemistry OT - Nuclear cofactors OT - Ulipristal acetate OT - Uterine myoma EDAT- 2017/12/12 06:00 MHDA- 2018/12/12 06:00 CRDT- 2017/12/12 06:00 PHST- 2016/12/09 00:00 [received] PHST- 2017/08/03 00:00 [accepted] PHST- 2017/12/12 06:00 [pubmed] PHST- 2018/12/12 06:00 [medline] PHST- 2017/12/12 06:00 [entrez] AID - 000480011 [pii] AID - 10.1159/000480011 [doi] PST - ppublish SO - Gynecol Obstet Invest. 2018;83(5):443-454. doi: 10.1159/000480011. Epub 2017 Dec 11.